The flowers are now available in the private market and through NOIDECS’ inclusion on the formulary of Europe’s largest patient real world data registry, Drug Science’s Project Twenty21. Under the agreement, NOIDECS is also expanding the range into other International territories.
The growing range of NOIDECS products is welcome news for the U.K. market, which has historically struggled with consistent supply of flower-based medical cannabis products. It also adds to the long line of products stocked by LYPHE Group pharmacy, Dispensary Green, which stocks more than 80% of all available brands in the market.
Dean Friday, CEO, LYPHE Group said of the new partnership: “We are pleased to welcome the talented team at Northern Green Canada into the U.K. market and consider them an important strategic supply partner as we begin the march across Europe and further afield with NOIDECS.”
Lisa McCormack, CEO, Northern Green Canada said in response: “We are delighted to support LYPHE Group as they build their NOIDECS range into a mainstay of the U.K. and European markets. Northern Green Canada’s approach is always focused on the production of quality medicine, and our EU GMP-certified products are a testament to this achievement.”